Major players in the domain

Kite Pharma (a Gilead company), Celgene and Autolus: Most active industry sponsors of CAR T cell clinical trials.

Numerous small biotech companies among top 10 developers driving innovation in the field, present ripe commercial opportunities for acquisition & collaboration.

Read Also: Chimeric Antigen Receptor (CAR) Overview

Participating companies, hospitals, drug manufacturers or universities and summary the relationship between them

• FUJIFILM Corporation announced on 05 April 2022, that it has completed the acquisition of a dedicated cell therapy manufacturing facility from Atara Biotherapeutics, Inc for USD 100 million. The 90,000 sq. ft. site is readily expandable to add capacity and has the flexibility to produce both clinical and commercial cell therapies including allogeneic T-cell and CAR T immunotherapies.
• Trinity College and St. James’s Hospital Dublin (SJH) in Ireland have entered into a strategic collaboration with Legend Biotech, a global biotechnology company developing, manufacturing and commercializing novel therapies. Together, they will develop 3D models exploring chimeric antigen receptor T-cell (CAR-T) cell therapies in solid tumors.
• Chimeric Therapeutics licenses entiviral vector plasmid system from University of Pennsylvania for CDH17 CAR T program.
• ONO Announces Expanded Collaboration with Fate Therapeutics on iPSC-derived CAR-T Cell and CAR-NK Cell Therapies for Solid Tumors.
• CellPoint, a cell therapy company developing CAR-T therapeutics for use at the point-of-care, announces an agreement with Lonza's Personalized Medicine Business Unit to employ Lonza's Cocoon® Platform for clinical manufacturing of CellPoint's CAR-T cell therapies at the point-of-care, more rapidly and at lower cost.
• Through the acquisition of CellPoint and AboundBio, respectively, Galapagos gains access to an innovative, scalable, decentralized and automated point-of-care cell therapy supply model as well as a next-generation fully human antibody-based therapeutics platform. Combined and supported by Galapagos as a fully integrated biopharma, they have the potential to disrupt the CAR-T treatment paradigm.
• Moderna and Carisma Establish Collaboration to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology.
• Catamaran Bio Expands Collaboration for CAR‑NK Cell Engineering with the University of Minnesota and Secures an Exclusive Patent License to Next Generation Manufacturing Technologies.
• Coeptis Therapeutics, Inc., a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced entry into an exclusive option agreement with the University of Pittsburgh for the rights to three chimeric antigen receptor T cell (CAR-T) technologies that offer the potential to address a range of hematologic and solid tumors.
• Luminary Therapeutics (Luminary Tx) and Case Western Reserve University have entered into a formal collaboration agreement that includes an option for Luminary to exclusively license a novel BAFF target for use in CAR-T (chimeric antigen receptor T cells) constructs.
• AbClon jointly with Asan Medical Center, will recruit participants with relapsed and refractory B-cell Non-Hodgkin's Lymphoma (NHL) in phase 1 clinical trials and determine the maximum tolerated dose and recommended dose for phase 2 clinical trials by analyzing safety and tolerability.
• South San Francisco-based Allogene Therapeutics inked a research collaboration deal with Stanford University to work on a novel nucleic acid delivery system for CAR-T therapy.
• New Delhi-based biotech startup Cellogen Therapeutics- working on cell based therapies - is planning to bring the new Chimeric antigen receptor (CAR)- T cell cancer therapy to India and has inked a knowledge sharing agreement with CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB) for the same.
• CARsgen partners with Shanghai Cancer Institute to advance CAR-T therapies The partners will work together to identify and develop novel CAR-T candidates as well as next-generation CAR-T technologies… CARsgen Therapeutics, a CAR-T cell therapy pioneer in China, has entered into a five year research and development agreement with Shanghai Cancer Institute for the advancement of CARsgen’s CAR-T cancer immunotherapeutics.

Read Also: Chimeric Antigen Receptor (CAR) Business Model

Government Initiatives

• Department of Biotechnology supported First CAR-T cell therapy conducted at ACTREC, Tata Hospital in Mumbai.
• CAR-T therapy receives Federal Government funding allowing young people with ALL to receive innovative treatment.
• A group of collaborating scientists received a $13.65 million federal grant to study and develop a CAR-T therapy that will genetically modify immune cells and potentially cure HIV, according to a press release from the University of California, Los Angeles (UCLA).
• The Ministry of Business, Innovation and Employment’s Partnership Scheme will contribute up to $4.9M over 5 years – 40% of the estimated cost – to help establish CAR T-cell manufacturing in New Zealand and develop new CAR T-cell therapies for clinical use.
• Prime Minister Justin Trudeau has announced more than $518 million in research infrastructure support through the Canada Foundation for Innovation (CFI). One of the 102 project recipients was ExCELLirate Canada, a group of institutions and researchers which includes Canadian Blood Services. With this grant, ExCELLirate Canada aims to develop the infrastructure for a national cellular therapy research platform with a focus on Chimeric Antigen Receptor (CAR) T-cell technology. CAR T-cell therapy has been successfully used to treat children and adults with some types of leukemia and lymphoma, and there is growing evidence that engineered immune cells have the potential to treat more types of cancer.
• CARAT - Chimeric Antigen Receptors (CARs) for Advanced Therapies:-an EU-funded collaborative research project involving 8 partners from 4 different European countries (France, Germany, Italy & United Kingdom).
• On November 23, 2021, the California Institute for Regenerative Medicine (CIRM) governing board approved a $4.1 million grant to enable University of California San Diego School of Medicine researchers to advance a new chimeric antigen receptor (CAR) T-cell therapy from the laboratory into the clinic.
• Lonza NEWS Collaboration to develop an automated CAR T-cell manufacturing system for clinics German oncology clinics are working with Optima Pharma to create an automated manufacturing unit for decentralised production of CAR T-cell therapies in treatment centres. 3d illustration of T cells Optima Pharma is collaborating with the Robert-Bosch-Krankenhaus (RBK) in Stuttgart, the Universitätsklinikum Heidelberg (UKHD) to develop an automated production system for chimeric antigen receptor (CAR) T-cell therapies. The project aims to improve quality, while also reducing the costs and time associated with CAR T cell production and is funded by the German Ministry of Economic Affairs, Labour and Housing Baden-Württemberg as part of the Forum Health Region Baden-Württemberg initiative.

About Effectual Services

Effectual Services is an award-winning Intellectual Property (IP) management advisory & consulting firm offering IP intelligence to Fortune 500 companies, law firms, research institutes and universities, and venture capital firms/PE firms, globally. Through research & intelligence we help our clients in taking critical business decisions backed with credible data sources, which in turn helps them achieve their organisational goals, foster innovation and achieve milestones within timelines while optimising costs.

We are one of the largest IP & business intelligence providers, globally serving clients for over a decade now. Our multidisciplinary teams of subject matter experts have deep knowledge of best practices across industries, are adept with benchmarking quality standards and use a combination of human and machine intellect to deliver quality projects. Having a global footprint in over 5 countries helps us to bridge boundaries and work seamlessly across multiple time zones, thus living to the core of our philosophy - Innovation is global, so are we !!!

Follow Us: LinkedIn, Twitter